Bevacizumab-based chemotherapy triggers Immunological effects in responding multi-treated recurrent ovarian cancer patients by favoring the recruitment of effector T Cell Subsets
Increasing evidence strongly suggests that bevacizumab compound impacts the
immunological signature of cancer patients and normalizes tumor vasculature. This study aims to
investigate the correlation between the clinical response to bevacizumab-based chemotherapy and
the improvement of immune fitness of multi-treated ovarian cancer patients. Peripheral blood
mononuclear cells (PBMCs) of 20 consecutive recurrent ovarian cancer patients retrospectively
selected to have received bevacizumab or non-bevacizumab-based chemotherapy (Bev group and